Contrasting Alvotech (ALVO) & Its Peers

Alvotech (NYSE:ALVOGet Free Report) is one of 283 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare Alvotech to related companies based on the strength of its dividends, institutional ownership, profitability, earnings, risk, valuation and analyst recommendations.

Volatility & Risk

Alvotech has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, Alvotech’s competitors have a beta of 1.05, indicating that their average stock price is 5% more volatile than the S&P 500.

Valuation and Earnings

This table compares Alvotech and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Alvotech $93.38 million -$513.58 million -6.15
Alvotech Competitors $596.33 million $31.29 million 7.62

Alvotech’s competitors have higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

44.9% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 0.5% of Alvotech shares are owned by insiders. Comparatively, 16.7% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Alvotech and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alvotech -967.97% N/A -68.89%
Alvotech Competitors -4,192.48% -172.83% -45.21%

Analyst Recommendations

This is a summary of current recommendations and price targets for Alvotech and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alvotech 0 1 1 0 2.50
Alvotech Competitors 1437 4577 11825 200 2.60

Alvotech currently has a consensus price target of $12.67, indicating a potential downside of 15.27%. As a group, “Biological products, except diagnostic” companies have a potential upside of 105.18%. Given Alvotech’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Alvotech has less favorable growth aspects than its competitors.

Summary

Alvotech competitors beat Alvotech on 11 of the 13 factors compared.

Alvotech Company Profile

(Get Free Report)

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.